Why have I been given this leaflet?

You have been receiving infusions of a brand of infliximab called Remicade®. Alder Hey is now changing to use a brand of infliximab called Remsima®. You will have the opportunity to discuss this with your consultant or nurse specialist before the change.

Why am I going to receive a different brand of infliximab?

When infliximab was first used, there was only one brand available - Remicade®. Now other brands of infliximab (biosimilars) have become available. One of these biosimilars is Remsima®.

Remsima® is better value for money for the NHS. Therefore we are switching patients already on Remicade® to Remsima®.

What is a biosimilar?

The World Health Organization (WHO) has defined a biosimilar (also called a similar biotherapeutic product) as a drug that is similar in terms of quality, safety and efficacy (effectiveness) to the original licensed product1.

This means that biosimilar medicines such as Remsima® work just as well and are just as safe as the original (Remicade®).

Remsima® is being used in lots of hospitals in the UK and the rest of Europe. Here at Alder Hey, it has been given to some of our gastroenterology patients since the middle of 2016. We haven’t seen any unexpected problems.

What will this mean for me?

- Your treatment will not change. Remsima® and Remicade® contain the same medicine (infliximab).
- You will have your infliximab at the same regular intervals as before. For example, if you usually have your infliximab infusion every eight weeks, this will not change.
- As usual, while you have the infusion you will have your temperature, heart rate, breathing rate and blood pressure checked. You will still need to have your usual blood tests.

1 http://www.who.int/biologicals/areas/biological_therapeutics/BIOOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf?ua=1
What will change?

- If you usually have your Remicade® (infliximab) infusion over one hour, you will get your first infusion of Remsima® (infliximab) over two hours. This is to make sure you don’t have any problems with Remsima®.

- As usual, we will be doing some tests to make sure everything is going OK with your treatment but you won’t have any more tests than usual. You will have the levels of infliximab in your blood and the levels of calprotectin in your faeces (poo) checked before your first Remsima® (infliximab) infusion, before your fourth infusion of Remsima® (infliximab) and after you have been receiving Remsima® (infliximab) for one year.

Where can I get more information?

You can speak to your nurse or doctor. Your parent or carer has been given more information so you can ask them to share it with you. http://napp.co.uk/products/patients/inflammatory-conditions/

This leaflet is based on the information contained in ‘Changing from Remicade® to Remsima® - My guide to changing infliximab’ (NAPP)

Who to contact for further details

This leaflet only gives general information. You must always discuss your individual treatment with the appropriate member of staff. Do not rely on this leaflet alone for information about your treatment.

This information can be made available in other languages and formats if requested.

Please note: Alder Hey Children’s NHS Foundation Trust is neither liable for the contents of any external internet site listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Alder Hey Children’s NHS Foundation Trust
Eaton Road
Liverpool
L12 2AP
Tel: 0151 228 4811
www.alderhey.nhs.uk

IRRYP/F/1 ©Alderhey2017 . Review date June 2019 PIAGM3